341
SupramoleculeS in Drug DiScovery anD Drug Delivery: methoDS anD protocolS
Index
Entropy�� 117, 118, 122, 189, 190
Equilibrium state �� 47, 230, 231
Exosome during secretion from the tissue ��26
Exosome from whole organs ��25–33
Exosome isolation��26–28
Exosomes ��25–33
Exothermic processes �� 171, 173, 192
External potential ��46, 47, 57, 64
Extracellular vesicles ��30
Extra sensitivity ��89
Extrusion �� 3, 253
F
Fluorescence ��95, 130, 188, 261
Fourier transform infrared spectroscopy ��76
Free energy calculations �� 110, 111
Freeze-drying �� 1–9, 164–166, 170, 258,
289, 318
Functionalities �� 14–15, 20, 22, 87, 119,
137, 221–232, 300
Functionalization �� 14, 22, 270
Functional phase �� 229, 231, 232
G
Gas delivery ��271–272
Gastric reflux ��270–271
Gemcitabine �� 127, 133, 136, 328, 330–337
Gibbs free energy (ΔG) ��46, 47, 117, 189, 194, 195
Glioblastoma multiforme ��175–185
Glove box �� 131, 132
Glutathione ��86, 88, 89, 252
Graphite �� 16, 17
Gromacs �� 48, 50–52, 54, 57, 61, 64, 68, 69
H
Half peak height �� 168, 225, 302
Heart exosomes ��27
Heat capacity ��164, 171, 196, 230
Heat-flux DSC �� 163, 164, 166
Heating rate�� 167, 171
Heating scans �� 225–227, 230, 231, 307
High energy states ��46
High vacuum techniques ��130, 135, 141, 142
1H-NMR spectroscopy �� 101, 142, 146
Host-guest interactions �� 2, 188
Host-guest complex ��2
Hybrids ��85, 139–149, 278
Hydrogels �� 86, 100, 127–137, 258, 262, 263,
271, 277, 278, 329
Hydrogen bonds �� 119, 155, 158, 189, 286
Hydrophilic blocks ��135, 139, 145, 149
Hydrophobic cores��73, 76, 77, 321
Hydrophobic drugs �� 71–81, 306
Hydrophobic interactions ��176, 189, 194, 229
2-hydroxypropyl-β-cyclodextrin
(2-HP-β-CD) �� 4, 110, 111
Hyperlipidemia associated diseases ��272
Hypertension ��100, 110, 268–269
Hyperthermia �� 86–90, 93, 96
I
Imaging ��29, 31, 95, 157
Improvement of the pharmacological
properties ��10, 70, 110, 152
In vitro �� 4, 9, 87, 89, 90, 140, 146,
148–149, 152, 165, 176, 202, 209–214, 249–256,
261, 262, 264–266, 268, 270–274
In vivo �� 4, 90, 135, 136, 139, 146, 149,
152, 176, 202, 250, 252–254, 256, 261, 264, 265,
267, 270, 273, 275
In vivo pharmacokinetic analysis ��185
Inclusion complexes ��2, 4–9, 110,
189, 190, 248, 251, 253, 256, 259, 265–268, 271,
288, 314
Indomethacin �� 72, 73, 76–80, 306,
308, 314
Inorganic ��85, 86, 163, 203, 260, 278
Interactions ��2, 14, 45–69, 87, 95, 101, 105, 106,
110, 155, 160, 164, 165, 168, 170, 176, 187–196,
244, 245, 251–253, 258, 267, 269, 274, 277, 288,
299, 303, 305, 308, 309, 314, 318–320, 330
Interdigitation ��308
Interfaces ��105, 106, 286, 291
Irbesartan (IRB) �� 4–6, 110–119, 165–172,
304–306, 316–322
Irbesartan2-HP-β-CD association ��110
Isothermal Titration Calorimetry (ITC) �� 188, 190, 191
Isotherms �� 167, 170, 189, 193, 225, 230, 302, 305
K
Kinetic phenomena��171
Kneading method ��3
L
LCST �� 152, 308
Lipid bilayers ��110, 300, 303–305, 309, 310, 320
Lipophilic drugs ��4, 46, 269, 277
Lipophilicity/Hydrophilicity �� 110, 264, 272
Liposomes �� 221–224, 227–230, 299–310, 315
Liver exosomes ��27
Losartan (LOS) �� 4, 6, 165–170, 192–194, 196
Losartan potassium ��166, 167, 190–192
Lower critical solution temperature
(LCST) ��88, 222, 226, 229–231
Lyophilization �� 6, 8, 9, 163, 166, 167, 170, 276
Lyotropic effect ��225

- 341/344